Page 2 - Nyse Ebs News Today

Boulder Hill Capital Management LP bought a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS – Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 40,600 shares of the biopharmaceutical company’s stock, valued at approximately $421,000. […]

Emergent has officially shipped its over the counter, original prescription strength NARCAN® Naloxone HCl Nasal Spray 4 mg to leading mass, drug/pharmacy...

StockNews.com initiated coverage on shares of Emergent BioSolutions (NYSE:EBS – Free Report) in a research note published on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Emergent BioSolutions Trading Down 2.9 % Shares of EBS stock opened at $4.97 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick […]

Emergent BioSolutions (NYSE:EBS – Get Free Report) is set to release its earnings data after the market closes on Tuesday, August 8th. Analysts expect Emergent BioSolutions to post earnings of ($0.95) per share for the quarter. Emergent BioSolutions has set its FY 2023 guidance at EPS.Individual that are interested in registering for the company’s earnings […]

Shares of Emergent BioSolutions Inc. (NYSE:EBS – Get Free Report) have earned a consensus rating of “Hold” from the five analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the […]

Shares of Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) have been given a consensus recommendation of “Hold” by the seven brokerages that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and two have given a buy recommendation to […]

Shares of Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) have received a consensus recommendation of “Hold” from the seven brokerages that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and two have given a buy recommendation to the company. […]

Prescott Group Capital Management L.L.C. purchased a new position in Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 91,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,075,000. Prescott Group Capital Management L.L.C. […]

StockNews.com initiated coverage on shares of Emergent BioSolutions (NYSE:EBS – Get Rating) in a report released on Thursday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Other equities research analysts have also recently issued reports about the company. Benchmark upgraded Emergent BioSolutions from a hold rating to a buy rating and […]

Emergent BioSolutions (NYSE:EBS – Get Rating) announced its earnings results on Tuesday. The biopharmaceutical company reported ($3.17) EPS for the quarter, missing the consensus estimate of ($1.67) by ($1.50), Briefing.com reports. Emergent BioSolutions had a negative net margin of 19.97% and a negative return on equity of 7.57%. The firm had revenue of $165.10 million […]